MedTrace Logo

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease

NCT04685265 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-03-22

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b as well as the effect of food and early signs of efficacy in patients with mild to moderate Parkinson´s disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

anle138b

capsule containing excipient and anle138b

DRUG

Placebo

matching placebo capsule containing excipient

Sponsors & Collaborators

  • Aptuit

    collaborator INDUSTRY

  • Quotient Sciences

    collaborator INDUSTRY

  • Nottingham University Hospitals NHS Trust

    collaborator OTHER

  • MODAG GmbH

    lead INDUSTRY

Principal Investigators

  • Nand Singh, BSc, MD, DPM, MFPM · Quotient Sciences Mere Way Ruddington Fields Ruddington Nottingham NG11 6JS, UK

  • Jonathan Evans, MD · Nottingham University Hospitals NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2022-11-07
Completion
2022-12-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04685265 on ClinicalTrials.gov